Alira Health Welcomes Marie-Aude Ohresser, Vice President, Regulatory Affairs

News
Category:
Published on:
May 5, 2020

BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, announces the appointment of Marie-Aude Ohresser to Vice President, Regulatory Affairs. Based in our Basel, Switzerland office, Marie-Aude will be instrumental in bolstering our EU regulatory capabilities as well as offering more comprehensive regulatory support globally.

Marie-Aude Ohresser

“We are delighted to welcome Marie-Aude to our Alira Health family. Marie-Aude joins us with a rich background and knowledge in the pharmaceutical industry including drug development, gene therapy, and various areas of regulatory affairs,” said Giacomo Basadonna, Chief Medical Officer, Alira Health. “Marie-Aude’s recruitment represents a fundamentally important step forward in expanding Alira Health’s global presence as a leading force in Regulatory Affairs for Pharma Products and Medical Devices, with the goal of transforming health care delivery for the benefit of patients around the world.”

“At this point in my career, I am ready for new challenges, and Alira Health is a perfect match for me. My new colleagues are dynamic, agile, and diligent and foster a supportive work environment,” said Marie-Aude. “I look forward to building on Alira Health’s existing pharma regulatory services as well as continuing to grow the synergies with our other divisions. I am confident that we are creating something extraordinary here, and the sky is the limit.”

Marie-Aude has over 20 years of experience in product development for the pharmaceutical industry. For the last decade, she worked with F. Hoffmann-La Roche, Ltd. as the Head of EU Liaison, Global Regulatory Affairs where she was responsible for planning and implementing strategy and activities such as optimizing resources and processes, developing KPIs, strengthening collaboration between affiliates and global regulatory departments to meet business needs. Marie-Aude has also led various cross-functional projects in the areas of regulatory records management and the pharmacovigilance system master file.

Most recently, Marie-Aude led changes related to Brexit across Roche’s pharmaceutical division. Prior to this, Marie-Aude was a regulatory strategist at Transgene SA and a project lead for a therapeutic vaccine in oncology. Marie-Aude has extensive knowledge of EU regulatory procedures and hands-on experience in preparing high-quality regulatory documentation.

To learn more about Marie-Aude, contact us.

Related news

Publications May 25, 2023
The EU Pharmaceutical Package: Introduction to Changes
Alira Health’s Regulatory experts explore how the proposed package will disrupt the European regulatory landscape and what it means for companies.
EU Pharma Regulatory
News February 21, 2023
Access and reimbursement pathways for digital health solutions and IVD devices
Digital therapeutics (DTx) are innovative solutions that use meaningful data to provide evidence-based decisions for the prevention, treatment, and management of diseases. Particular(...)
Diagnostics Digital Therapeutics Market Access Regulatory Research and Development
Events February 10, 2023
Regulatory Roundup
We are pleased to announce that we are joining Regulatory Roundup as sponsors and speakers. This unique event is hosted by MassMEDIC, the largest regional medtech association in the United States.
Regulatory
Blog January 19, 2023
Medical Device Regulation in 2023: A Window of Opportunity
We spoke with our team of regulatory experts about the recent news regarding the MDR and the opportunity it presents to device manufacturers in 2023.
Medical Devices MedTech Regulatory
Blog January 11, 2023
Regulatory Strategy for Registering Rare Disease Products in the EU: What You Need to Know
Given that the regulation is likely to change considerably, drug developers may need to revisit their development strategy. In the meantime, building a strategy around these evergreen(...)
EU Rare Disease Regulatory
Blog December 21, 2022
2022 Recap: Your Favorite Alira Health Publications
In 2022, the Alira Health team of scientists, strategists, economists, clinicians, and biostatisticians shared actionable insights, industry thought leadership, and leading-edge guidance(...)
Clinical Digital Health Market Access MedTech Pharma Regulatory
Multimedia December 17, 2022
Webinar Replay: Partnering with Patients to Streamline Trial Operations: Protocol to Regulatory Submission in 60 days
Learn how patients and patient advocacy organizations can be directly enabled as powerful partners to facilitate all stages of DCT deployment, from protocol design, recruitment, engagement(...)
Clinical Trials Patient Centricity Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.